Stockscreener 앱 받기
12.61
5.54%
-0.74
전일 마감가:
$13.35
열려 있는:
$13.28
하루 거래량:
328.61K
Relative Volume:
0.90
시가총액:
$363.96M
수익:
$66.59M
순이익/손실:
$-104.93M
주가수익비율:
-2.5475
EPS:
-4.95
순현금흐름:
$-96.48M
1주 성능:
-3.81%
1개월 성능:
-15.08%
6개월 성능:
+77.86%
1년 성능:
+160.00%
1일 변동 폭
$12.50
$13.28
1주일 범위
$12.50
$13.98
52주 변동 폭
$4.09
$17.15
Enanta Pharmaceuticals Inc Stock (ENTA) Company Profile
명칭
Enanta Pharmaceuticals Inc
전화
617 607 0800
주소
4 KINGSBURY AVENUE, WATERTOWN, MA
ENTA을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ENTA
Enanta Pharmaceuticals Inc
|
12.61 | 385.32M | 66.59M | -104.93M | -96.48M | -4.95 |
|
VRTX
Vertex Pharmaceuticals Inc
|
441.36 | 111.36B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.98B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
800.01 | 50.33B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
359.27 | 47.46B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
338.19 | 37.43B | 4.98B | 69.59M | 525.67M | 0.5197 |
Enanta Pharmaceuticals Inc Stock (ENTA) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-11-14 | 개시 | JP Morgan | Overweight |
| 2025-10-01 | 업그레이드 | Jefferies | Hold → Buy |
| 2025-07-28 | 재개 | H.C. Wainwright | Buy |
| 2023-08-09 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2023-08-08 | 다운그레이드 | Jefferies | Buy → Hold |
| 2022-12-09 | 개시 | H.C. Wainwright | Buy |
| 2022-07-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2022-06-01 | 업그레이드 | Evercore ISI | Underperform → In-line |
| 2021-10-07 | 개시 | Jefferies | Buy |
| 2021-09-09 | 개시 | SVB Leerink | Mkt Perform |
| 2021-01-29 | 업그레이드 | JP Morgan | Underweight → Neutral |
| 2020-11-24 | 개시 | Evercore ISI | Underperform |
| 2020-08-28 | 재개 | ROTH Capital | Buy |
| 2020-08-26 | 개시 | Piper Sandler | Overweight |
| 2020-07-27 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2020-03-17 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2019-11-22 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2019-09-26 | 다운그레이드 | JP Morgan | Neutral → Underweight |
| 2019-05-24 | 개시 | Wolfe Research | Outperform |
| 2019-04-23 | 업그레이드 | Berenberg | Hold → Buy |
| 2018-12-13 | 개시 | Berenberg | Hold |
| 2018-06-06 | 개시 | ROTH Capital | Buy |
| 2018-02-08 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2018-01-02 | 다운그레이드 | RBC Capital Mkts | Outperform → Sector Perform |
| 2017-11-21 | 재확인 | RBC Capital Mkts | Outperform |
| 2017-09-15 | 개시 | RBC Capital Mkts | Outperform |
| 2017-07-11 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
| 2016-04-28 | 다운그레이드 | JMP Securities | Mkt Outperform → Mkt Perform |
| 2016-02-09 | 재확인 | Barclays | Underweight |
| 2015-10-23 | 다운그레이드 | Barclays | Equal Weight → Underweight |
| 2015-10-23 | 업그레이드 | JMP Securities | Mkt Perform → Mkt Outperform |
모두보기
Enanta Pharmaceuticals Inc 주식(ENTA)의 최신 뉴스
Technical Reactions to ENTA Trends in Macro Strategies - Stock Traders Daily
JPM26: Enanta outlines strategy to lead in RSV therapeutics - Yahoo Finance
Chipmakers Recap: Is Enanta Pharmaceuticals Inc stock affected by interest rate hikesPortfolio Update Report & Free Technical Pattern Based Buy Signals - Bộ Nội Vụ
Income Plays: What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsJuly 2025 Market Mood & Growth Focused Entry Point Reports - Bộ Nội Vụ
Downgrade Watch: Why is Enanta Pharmaceuticals Inc stock going upJuly 2025 Summary & Trade Opportunity Analysis - baoquankhu1.vn
Is Enanta Pharmaceuticals Inc. stock trading at a premium valuationJuly 2025 Trade Ideas & Reliable Trade Execution Plans - Улправда
Will Enanta Pharmaceuticals Inc. stock gain from strong economyAnalyst Downgrade & Safe Swing Trade Setups - Улправда
Enanta Pharmaceuticals, Inc.Common Stock (NQ: ENTA - FinancialContent
What makes Enanta Pharmaceuticals Inc. stock attractive to growth fundsTrade Execution Strategies & Our Experts Decode Market Noise for You - bollywoodhelpline.com
Enanta advances RSV and immunology pipeline with key milestones ahead By Investing.com - Investing.com Nigeria
Enanta Pharmaceuticals (NASDAQ:ENTA) Receives "Buy" Rating from HC Wainwright - MarketBeat
Enanta Pharma (ENTA) Receives Buy Rating, Price Target Maintained | ENTA Stock News - GuruFocus
Baird reiterates Outperform rating on Enanta Pharmaceuticals stock By Investing.com - Investing.com UK
Will Enanta Pharmaceuticals Inc. stock benefit from automationQuarterly Portfolio Summary & Daily Oversold Bounce Ideas - Улправда
Why Enanta Pharmaceuticals Inc. stock appeals to analystsTrade Performance Summary & Fast Entry High Yield Stock Tips - ulpravda.ru
Is Enanta Pharmaceuticals Inc. stock a safe haven assetWeekly Trend Report & Weekly Stock Breakout Alerts - ulpravda.ru
What valuation multiples suggest for Enanta Pharmaceuticals Inc. stock2025 Breakouts & Breakdowns & Fast Moving Market Watchlists - Улправда
Is Enanta Pharmaceuticals Inc. stock a bargain at current levelsJuly 2025 Rallies & Risk Controlled Daily Plans - Улправда
Enanta Pharmaceuticals Provides Update on its Research and Development Programs and 2026 Outlook - PharmiWeb.com
Enanta advances RSV and immunology pipeline with key milestones ahead - Investing.com India
Trading the Move, Not the Narrative: (ENTA) Edition - Stock Traders Daily
Enanta Pharma (ENTA) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Enanta Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference - BioSpace
Enanta Pharmaceuticals to Present at the Wells Fargo Securities 2013 Healthcare Conference - AOL.com
Enanta Pharmaceuticals Insider Ups Holding During Year - Yahoo Finance
Meme Stocks: Why Enanta Pharmaceuticals Inc 9EP stock benefits from AI revolution2025 Geopolitical Influence & Free Long-Term Investment Growth Plans - moha.gov.vn
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ENTA SEC FilingsEnanta Pharmaceuticals Inc 10-K, 10-Q, 8-K Forms - Stock Titan
Enanta Pharmaceuticals (ENTA) Surges 5.9%: Is This an Indication of Further Gains? - Yahoo Finance
What hedge fund activity signals for Enanta Pharmaceuticals Inc. stock2025 Market Outlook & Daily Growth Stock Investment Tips - Улправда
How Enanta Pharmaceuticals Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Technical Pattern Recognition Alerts - Улправда
Does Enanta Pharmaceuticals Inc. stock trade at a discount to peersMarket Movement Recap & Smart Allocation Stock Tips - Улправда
Enanta Pharmaceuticals, Inc. (NASDAQ:ENTA) Stock Catapults 27% Though Its Price And Business Still Lag The Industry - simplywall.st
Rate Hike: Will Enanta Pharmaceuticals Inc. stock see insider buyingTrade Performance Summary & Daily Profit Focused Stock Screening - Улправда
Will Enanta Pharmaceuticals Inc. (9EP) stock see insider accumulationTrade Risk Report & Long-Term Safe Investment Ideas - Улправда
What margin trends mean for Enanta Pharmaceuticals Inc. stockJuly 2025 Retail & Free Verified High Yield Trade Plans - Улправда
Why Enanta Pharmaceuticals Inc. stock is considered a top pickMarket Activity Summary & Precise Trade Entry Recommendations - Улправда
Will Enanta Pharmaceuticals Inc. stock benefit from upcoming earnings reportsRate Hike & Accurate Technical Buy Alerts - Bölüm Sonu Canavarı
Aug Breakouts: Will Enanta Pharmaceuticals Inc. (9EP) stock outperform Dow Jones2025 Market Sentiment & Weekly High Momentum Picks - Улправда
Is Enanta Pharmaceuticals Inc. stock a buy in volatile marketsJuly 2025 Retail & Low Drawdown Momentum Ideas - DonanımHaber
Will Enanta Pharmaceuticals Inc. stock see insider buyingMarket Trend Report & Fast Exit and Entry Strategy Plans - Улправда
(ENTA) Movement Within Algorithmic Entry Frameworks - Stock Traders Daily
Enanta Pharmaceuticals (NASDAQ:ENTA) Share Price Crosses Above 200-Day Moving AverageWhat's Next? - MarketBeat
Have Insiders Sold Enanta Pharmaceuticals Shares Recently? - simplywall.st
Enanta Pharmaceuticals falls on public offering of common stock - MSN
Enanta Pharmaceuticals Inc (ENTA) 재무 분석
매출
순이익
현금흐름
주당 순 이익
Enanta Pharmaceuticals Inc 주식 (ENTA) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Trout Harry R. III | See Remarks |
Dec 05 '25 |
Sale |
14.23 |
542 |
7,713 |
16,348 |
| Rottinghaus Scott T. | Chief Medical Officer |
Dec 05 '25 |
Sale |
14.23 |
798 |
11,356 |
21,792 |
| Luu Brendan | Chief Business Officer |
Dec 05 '25 |
Sale |
14.23 |
1,394 |
19,837 |
38,329 |
| Kieffer Tara Lynn | Chief Product Strategy Officer |
Dec 05 '25 |
Sale |
14.23 |
2,106 |
29,968 |
30,620 |
| Or Yat Sun | Chief Scientific Officer |
Dec 05 '25 |
Sale |
14.23 |
2,390 |
34,010 |
371,392 |
| Luly Jay R. | President and CEO |
Dec 05 '25 |
Sale |
14.23 |
4,743 |
67,493 |
858,026 |
4.73%
0.92%
자본화:
|
볼륨(24시간):